BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37291850)

  • 1. LINC00641 impeded the malignant biological behaviors of papillary thyroid carcinoma cells via interacting with IGF2BP1 to reduce GLI1 mRNA stability.
    Meng D; Zhao S; Wu L; Ma X; Zhao D; Li Z
    Hum Exp Toxicol; 2023; 42():9603271231180856. PubMed ID: 37291850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long noncoding RNA SNHG22 increases ZEB1 expression via competitive binding with microRNA-429 to promote the malignant development of papillary thyroid cancer.
    Gao H; Sun X; Wang H; Zheng Y
    Cell Cycle; 2020 May; 19(10):1186-1199. PubMed ID: 32306838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing long non-coding RNAs nicotinamide nucleotide transhydrogenase antisense RNA 1 inhibited papillary thyroid cancer cell proliferation, migration and invasion and promoted apoptosis via targeting miR-199a-5p.
    Wang D; Zheng Y
    Endocr J; 2021 May; 68(5):583-597. PubMed ID: 33612561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway.
    Zhao J; Li Z; Chen Y; Zhang S; Guo L; Gao B; Jiang Y; Tian W; Hao S; Zhang X
    Int J Oncol; 2019 Jan; 54(1):315-325. PubMed ID: 30387841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long noncoding RNA CASC9 promotes the proliferation and metastasis of papillary thyroid cancer via sponging miR-488-3p.
    Chen Y; Li Y; Gao H
    Cancer Med; 2020 Mar; 9(5):1830-1841. PubMed ID: 31943867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long noncoding RNA cancer susceptibility candidate 2 suppresses papillary thyroid carcinoma growth by inactivating the AKT/ERK1/2 signaling pathway.
    Huang F; Zhang Q; Chen W; Zhang H; Lu G; Chen J; Qiu C
    J Cell Biochem; 2019 Jun; 120(6):10380-10390. PubMed ID: 30609134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circ_0079558 promotes papillary thyroid cancer progression by binding to miR-26b-5p to activate MET/AKT signaling.
    Zheng H; Fu Q; Ma K; Shi S; Fu Y
    Endocr J; 2021 Nov; 68(11):1247-1266. PubMed ID: 34565758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA HOTTIP promotes papillary thyroid carcinoma cell proliferation, invasion and migration by regulating miR-637.
    Yuan Q; Liu Y; Fan Y; Liu Z; Wang X; Jia M; Geng Z; Zhang J; Lu X
    Int J Biochem Cell Biol; 2018 May; 98():1-9. PubMed ID: 29474928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of long non-coding RNA LINC00982 suppresses cell proliferation and tumor growth of papillary thyroid carcinoma through PI3K-ATK signaling pathway.
    Xu D; Yu J; Zhuang S; Zhang S; Hong Z; Yuan C
    Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31262968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel lncRNA n384546 promotes thyroid papillary cancer progression and metastasis by acting as a competing endogenous RNA of miR-145-5p to regulate AKT3.
    Feng J; Zhou Q; Yi H; Ma S; Li D; Xu Y; Wang J; Yin S
    Cell Death Dis; 2019 Jun; 10(6):433. PubMed ID: 31160577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcription Factor E2F1 Exacerbates Papillary Thyroid Carcinoma Cell Growth and Invasion
    Yang J; Ying Y; Zeng X; Liu J; Xie Y; Deng Z; Hu Z; Li Z
    Anal Cell Pathol (Amst); 2022; 2022():7081611. PubMed ID: 35592867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXE1 supports the tumor promotion of Gli2 on papillary thyroid carcinoma by the Wnt/β-catenin pathway.
    Ma J; Huang X; Li Z; Shen Y; Lai J; Su Q; Zhao J; Xu J
    J Cell Physiol; 2019 Aug; 234(10):17739-17748. PubMed ID: 30793770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long noncoding RNA LINC00520 accelerates progression of papillary thyroid carcinoma by serving as a competing endogenous RNA of microRNA-577 to increase Sphk2 expression.
    Sun Y; Shi T; Ma Y; Qin H; Li K
    Cell Cycle; 2020 Apr; 19(7):787-800. PubMed ID: 32075502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing of Long Non-coding RNA ENST00000606790.1 Inhibits the Malignant Behaviors of Papillary Thyroid Carcinoma through the PI3K/AKT Pathway.
    Zuo Z; Liu L; Song B; Tan J; Ding D; Lu Y
    Endocr Res; 2021 Feb; 46(1):1-9. PubMed ID: 32791924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BGL3 inhibits papillary thyroid carcinoma progression via regulating PTEN stability.
    Zhao M; Yang F; Sang C; Yan C; Wang Z
    J Endocrinol Invest; 2021 Oct; 44(10):2165-2174. PubMed ID: 33543443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA PFAR facilitates the proliferation and migration of papillary thyroid carcinoma by competitively binding to miR-15a.
    Fang T; Yu K
    Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3037-3048. PubMed ID: 37874339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long non-coding RNA LINC00152 promotes cell growth and invasion of papillary thyroid carcinoma by regulating the miR-497/BDNF axis.
    Sun Z; Guo X; Zang M; Wang P; Xue S; Chen G
    J Cell Physiol; 2019 Feb; 234(2):1336-1345. PubMed ID: 30146756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long non-coding RNA LIFR-AS1 suppressed the proliferation, angiogenesis, migration and invasion of papillary thyroid cancer cells via the miR-31-5p/SIDT2 axis.
    Yi D; Zhang D; He J
    Cell Cycle; 2021 Dec; 20(24):2619-2637. PubMed ID: 34781815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long noncoding RNA PVT1 enhances the viability and invasion of papillary thyroid carcinoma cells by functioning as ceRNA of microRNA-30a through mediating expression of insulin like growth factor 1 receptor.
    Feng K; Liu Y; Xu LJ; Zhao LF; Jia CW; Xu MY
    Biomed Pharmacother; 2018 Aug; 104():686-698. PubMed ID: 29803929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SP1-induced upregulation of long noncoding RNA LINC00313 contributes to papillary thyroid cancer progression via the miR-422a.
    Yan DG; Liu N; Chao M; Tu YY; Liu WS
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1134-1144. PubMed ID: 30779082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.